Conagen Expands Portfolio Beyond Gamma-Decalactone to 20 new non-GMO Lactones


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Conagen, a Boston-based biotechnology company focusing on research and development, announced today its breakthrough development in the commercial production of natural aromatic compound, γ-Decalactone from natural substrates using its proprietary technology.

Conagen, a Boston-based biotechnology company focusing on research and development, announced today its breakthrough development in the commercial production of natural aromatic compound, γ-Decalactone from natural substrates using its proprietary technology. Found in many ripe fruits and particularly peaches, γ-Decalactone is a versatile compound used commercially in formulations with distinctive fruit flavors of peach, apricot and strawberry in food, beverage, fragrance, nutrition, renewable materials, and pharmaceutical markets.

The technology created for the γ-Decalactone product provides for more than 20 different lactones, many of which have not been available commercially because of a lack of reliable sources. This positions the company as a leader in the world of ingredient development. "The strengthening and expansion of Conagen's lactone production platform will better meet consumers' demand for nature-based, clean ingredients," said Oliver Yu, Ph.D., co-founder, and CEO of Conagen.

The compound is a member of a much larger family of lactones. Variations in the structures of lactones define their unique sensory properties with mainly fruity and buttery characteristics. These diverse characteristics create a wider spectrum of application options for manufacturers that use lactone flavors in their products.

"Conagen's lactone products are natural and non-GMO, making them ideal for use in a variety of consumer products," said Vice President of Research and Development, Casey Lippmeier, Ph.D.

For the last 10 years, Conagen has successfully developed one of the largest portfolios of ingredient products for its customers. 

Tags : #conagenexpandsportfoliogammadecalactone

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026